Page 183 - CW E-Magazine (18-2-2025)
P. 183

Special Report                                                                   Special Report


 Table 3: China’s support to fermentation units  Table 5: Disadvantages faced by Indian API manufacturers vis-à-vis China  Substantial funding must be given

 Development of ancillary   Investor-friendly labour   China  India       to industry for R&D and there needs
 Infrastructure support  Cost of utilities & capital  Capacity  industries for supplies  laws  Borrowing costs  4-5%  12-14%  to be a five-year plan for developing
 •  Land at preferential   •  Local currency fi nance   •  Capacity has been   •  Effi cienct and   •  Workers can be hired   some critical processes.
 price ($10/sq.m.) with   at average interest rate   created taking   continuous supply of   and terminated as per   Raw material costs  x  1.25-1.30x
 excellent connectivity to   of 5% per annum.  into account world   maize/liquid glucose,   company policy, without
 ports and airports.  •  In summer, cost of   demand. Thus, per unit   which are basic raw   interference of local   Power costs  Rs. 7.368 per kWh  Rs. 6.172 per kWh  CONCLUSION
 •  Located in areas where   production may increase   overheads, depreciation   materials for fermentaion.  government or labour   If India is to achieve its goal of
 temperature remains   8-9% compared to   and operation costs are   unions.  Logistics infrastructure costs  x-2%  x
 below 22°C for 9-10   winter, mainly due to use   lower.  •  Effi ciency and company   emerging as a developed nation by
 months in a year.  in utilities to maintain   interests are top   Labour costs  1.8x  x
 •  Up to 100-MW power   cooler temperature.  priorities.                 2047, the chemical industry will have
 plant with steam and   Labour productivity  1.5x       x                 to grow substantially. Time is running
 dual power transmission
 lines.  Scale of operations       1.3-1.4x             x                 out to put in place policy measures to
 •  Common effl uent
 treatment plant with   Set up and production costs  0.80-0.85x  x        ensure the same. Are the powers that
 30,000-tpd capacity.                                                     be listening?
        Overall costs              0.7-0.8x             x
 Table 4: Issues & technological readiness with respect to production of fermentation-based products  Ease of doing business ranking     ABOUT THE AUTHOR
 API  Issues   Technology Readiness  • Enforcing contracts  5  163            Mr.  Y.H. Gharpure, Chairman
 Oxytetracycline  Capital intensive, strain development/technology access  Strains research and scale required.  • Registering property  28  158  and Managing Director (CMD),
 Tetracycline  Capital intensive  Strains research and scale required.  • Paying taxes  105  115  Industrial Polyclinic (India) Pvt. Ltd.,
                                                                            was Managing Director of
 Ampicillin  Total dependence on 6-APA, a KSM; fermentation-based Strains research and scale required.  • Trading across borders  56  68  Hindustan  Antibiotics Ltd., Pune
 Cephalosporins  Large scale fermentation capability, strain development/ Strains research required.  Table 6: Approval duration for an API plant  till 1985. He is also CMD, Gharpure
 technology access  Approval                           Duration (months)    Consulting Engineers Pvt. Ltd.;
 Penicillin G  Large scale fermentation capability, strain development/ Strains research required.  Central Pollution Control Board (CPCB)  9-12  Founder  President, Technology
 technology access                                                          Transfer Association;  Founder
 Streptomycin  Strain development/technology access  Strains research required.  Plant set-up  18-24  Chairman, Voluntary  Executives
                                                                            Forum of India; and former Presi-
        Pollution load certifi cate
 Neomycin  Strain development/technology access  Strains research required.  Source: Indian API Industry-Reaching the potential, KPMG-CII Report  3-12  dent, Indo Japan Business Council.
 Doxycycline  Strain development  Strain research required.  globally at marginal costing (with  to help. The Chinese economy has
 Vitamin C  No viable cost-effective technology for KSM, 2-Keto-L- Viable technology for production of the KSM   some contribution to profits)(4).  been growing with an export contri-  For further reading
 gluconic acid, manufactured by microbial oxidation  through microbial oxidation to be deve-  bution 20-40% (currently around
 loped.  Other factors                   20%) and India has to try achieve  1.  ‘$1-trillion chemical industry is
 Vitamin B12  Strain development  Strains research required.  Indian industry is also subject  likewise.  pie-in-the-sky, but opportunities
 Erythromycin  Non-availability of TIOC technology; large scale fermen- Technology  for production  of  TIOC to be   to  high interest rates, high logistic   abound’, Ravi Raghavan, Chemical
 tation capability, strain development/technology access  developed.  costs, etc. Getting the many approvals   If interest rates are not brought   Weekly, Oct. 20, 2024.
 Clarithromycin  Strain development  Strains research required.  needed  for setting  up  a unit  takes  down, exporters must get interest   2.  What ails Indian Chemical Indus-
       anywhere from 30-48 months  subsidy as compensation.
 Meropenem  Local intermediate manufacturers are either small or  Strains research required.  (Table 5, 6):  try? N.S.Venkataraman, Director,
 depend on China; Strain development       Logistical costs must also be      Nandini Consultancy Centre,
 Clindamycin  Strain development/technology access  Strains research required; viable technology   Remedial measure  brought down. Currently, it is 16-18%,   Chemical  Weekly, January  28,
                                                                              2025.
 for manufacture of API from KSMs available.  First and foremost, there is an  and  efforts  are  ongoing  to  bring  it   3.  ‘Will the Production Link Incen-
 Imipenem  Strain development, inferior downstream processing  Strains research required.  urgent need to make GST compre-  down to 8-9%; these efforts must   tive  Scheme  for pharmaceuticals
 Doripenem  Strain development, inferior downstream processing  Strains research required.  hensive.  accelerate.  deliver?’ Y.H. Gharpure, Chemical
 Potassium clavu- Large scale fermentation capability, strain development/ Strains research required.  Only economically sized plants   Power  costs  need to be brought   Weekly, Sep. 22, 2020.
 lanate/Clavulanic technology access  should be put up to meet not only  down, and at the same time supply of   4.  ‘High cost of manufacturers basic
 acid  current and prospective Indian  uninterrupted  power is a must, parti  organic chemicals – reasons &
 Betamethasone  Strain development/technology access  Strains research required.  demand, but also export demand.  cularly for continueous plants. This will   remedies’,  Y.H. Gharpure and
 Prednisolone   Strain development/technology access  Strains research required.  If  a  ‘Developed  India  by  2047’  eliminate the current practise of having   Swaminathan, Seminar organised
 Dexamethasone  Strain development/technology access  Strains research required.  goal is to be achieved, just meet-  a generator backup, which adds to   by Indian Chemical Manufacturers
       ing internal demand is not likely  investment cost and cost of production.
 Source: APIs -Status, Issues, Technology Readiness and Challenges, TIFAC, July 2020  Association, 1975.

 182  Chemical Weekly  February 18, 2025  Chemical Weekly  February 18, 2025                           183


                                      Contents    Index to Advertisers    Index to Products Advertised
   178   179   180   181   182   183   184   185   186   187   188